Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: Preliminary results of a case–control study
To access this article, please choose from the options below
PII: S0748-7983(10)00098-3
doi:10.1016/j.ejso.2010.04.010
© 2010 Elsevier Ltd. All rights reserved.
